DeoBioSciences, Inc.

DeoBioSciences is developing a treatment against advanced metastatic cancer for people and pets.

Print
Claim My Business
Form C
View on Netcapital
Security Type
Debt
Min Investment
$100
Location
Lilburn, GA
Offering Date
March 24, 2021
Expected Close Date
March 15, 2022
Target Raise
$10.00K-$1.07M
Security Price
$50
Deal Notes

Price Per Share: $50.00

Valuation
$15,600,000
Website
deobiosciences.com
Number of Employees
1
Cash
$1,151
Revenue
$0
Short Term Debt
$4,035
Cost of Goods
$0
Long Term Debt
$245,588
Net Income
$19,427

Company Description

DeoBioSciences (DBS) is a stealth mode, R&D stage, virtual biotech developing a cancer drug, based on a naturally occurring compound, that selectively kills both early and advanced stage cancer cells from humans and, potentially, dogs and cats as well.

We are reverse engineering the drug from anecdotal data and reports of human efficacy and safety from bioprospecting sources and also corroborating studies involving molecular homologues in humans and animals that further affirmed safety and efficacy projections. So far, our pre-clinical lab results have corroborated and met all our predictions for safety and performance.

Key Deal Facts

Major biotechs and pharmas have confirmed, in writing, their interest in pursuing in-licensing or partnerships, upon the presentation of more positive data
Cornell University's top scientists, among others, are anxious to continue working with us to take our research to the next level
We're not a “one trick pony”-- our stealth tech has other potential applications that we will pursue to maximize our chances of success

Use of Proceeds

  • Pre-Clinical Drug Manufacturing 27.1%
  • Pre-Clinical animal trials/studies 22.9%
  • Payroll & Benefits 31.4%
  • R&D consultants/contractors 8.2%
  • Admin. Operations, Rent, IP & Legal, Miscellaneous 5.5%
  • Intermediary fees 4.9%

 

Management Team / Advisory Board Bios

John F Adamson, Co-Founder, CEO, & President

Dr. H.G. Schmidt
Lead Cancer Research Scientist @ Cornell University

Dr. C.P. Wellstone
Veterinary Clinical Trial Lead Strategist and Scientist

Deal Notes

Price Per Share: $50.00

Amount Raised : $112,350
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Debt is something, usually money, borrowed by one party from another. Debt is used by many corporations and individuals to make large purchases that they could not afford under normal circumstances. A debt arrangement gives the borrowing party permission to borrow money under the condition that it is to be paid back at a later date, usually with interest.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment